慢性肝病合并慢性肾脏病患者的临床特征分析

肝脏 ›› 2023, Vol. 28 ›› Issue (5): 518-522.

慢性肝病合并慢性肾脏病患者的临床特征分析

康玮玮, 刘立伟, 张嫄, 钟蕊, 冯丽丽, 陈煜

100069 首都医科大学附属北京佑安医院肝病中心四科,肝衰竭与人工肝治疗研究北京市重点实验室(康玮玮,刘立伟,钟蕊,冯丽丽,陈煜),超声与功能诊断中心(张嫄)

收稿日期:2022-10-25 出版日期:2023-05-31 发布日期:2023-08-29
通讯作者: 陈煜,Email:chybeyond1071@ccmu.edu.cn
基金资助:
北京市自然科学基金 (7222094);北京市医院管理中心“登峰”计划专项经费资助(DFL20221501);高层次公共卫生技术人才建设项目资助(学科带头人-01-12)

Clinical characteristics of nephropathy in patients with chronic liver disease combined with chronic kidney disease

KANG Wei-wei¹, LIU Li-wei¹, ZHANG Yuan², ZHONG Rui¹, FENG Li-li¹, CHEN Yu¹

1. The Fourth Department of Liver Disease Center of Beijing You’an Hospital, Capital Medical University, Beijing Key Laboratory of Liver Failure and Artificial Liver Therapy, Beijing 100069, China;
2. Ultrasound and Functional Diagnosis Center of Beijing You'an Hospital, Capital Medical University, Beijing 100069, China

Received:2022-10-25 Online:2023-05-31 Published:2023-08-29
Contact: CHEN Yu, Email: chybeyond1071@ccmu.edu.cn

摘要/Abstract

摘要： 目的探讨慢性肝病合并慢性肾脏病(chronic kidney disease, CKD)患者的临床特征。方法纳入2020年6月至2021年12月于首都医科大学附属北京佑安医院肝病中心四科就诊的慢性肝病合并CKD患者65例,根据CKD分期分为1-2期组32例,3期组24例,4-5期组9例。比较各组患者临床特征,采用logistic回归分析慢性肝病患者CKD进展至4-5期的危险因素。结果随着CKD分期进展,血β2微球蛋白(CKD1-2期2.6 mg/L,CKD3期6.9 mg/L,CKD4-5期12.8 mg/L,P<0.01)、尿α1微球蛋白(CKD1-2期23.3 mg/L,CKD3期30.1 mg/L,CKD4-5期72.6 mg/L,P=0.001)、尿β2微球蛋白(CKD1-2期0.4 mg/L,CKD3期0.5 mg/L,CKD4-5期8.3 mg/L,P=0.005)水平显著增加,尿肌酐(CKD1-2期8881 μmol/L,CKD3期5512 μmol/L,CKD4-5期4388 μmol/L,P<0.01)、尿钠(CKD1-2期111.4 mmol/L,CKD3期75.8 mmol/L,CKD4-5期73.2 mmol/L,P<0.01)水平显著降低;双侧肾门动脉阻力指数(右侧CKD1-2期0.69,CKD3期0.77,CKD4-5期0.74,P=0.010,左侧CKD1-2期0.69,CKD3期0.76,CKD4-5期0.78,P=0.009)及段动脉阻力指数(右侧CKD1-2期0.66,CKD3期0.71,CKD4-5期0.72,P=0.034,左侧CKD1-2期0.66,CKD3期0.69,CKD4-5期0.73,P=0.027)亦随CKD分期增加而逐渐增加。多因素logistic回归分析发现,较高的血视黄醇结合蛋白(OR=1.073, 95% CI:1.006~1.145,P=0.032)、血β2微球蛋白(OR=1.932, 95% CI:1.233~3.027,P=0.004)是慢性肝病合并CKD患者进展至CKD4-5期的独立危险因素。结论监测慢性肝病合并CKD患者血和尿的生物学标志物,有助于及早发现慢性肝病患者CKD进展、及时干预并改善预后。

关键词: 慢性肝病, 慢性肾脏病, 临床特征, 危险因素

Abstract: Objective To investigate the clinical characteristics of chronic kidney disease (CKD) progression in patients with chronic liver disease combined with CKD.Methods Patients with chronic liver disease complicated with CKD admitted to our hospital from June 2020 to December 2021 were enrolled, they were divided into stage 1-2 group, stage 3 group and stage 4-5 group according to CKD staging. The clinical characteristics of patients in each group were compared. Logistic regression was used to analyze the risk factors for the progression of CKD to stage 4-5 in patients with chronic liver disease.Results A total of 65 patients with chronic liver disease complicated with CKD were included. With the progression of CKD staging, the levels of serum β2 microglobulin (CKD1-2 2.6 mg/L,CKD3 6.9 mg/L,CKD4-5 12.8 mg/L, P<0.001), urinary α1 microglobulin (CKD1-2 23.3 mg/L, CKD3 30.1 mg/L, CKD4-5 72.6 mg/L, P=0.001), urinary β2 microglobulin (CKD1-2 0.4 mg/L, CKD3 0.5 mg/L, CKD4-5 8.3 mg/L, P=0.005) increased significantly, while urinary creatinine (CKD1-2 8881 μmol/L, CKD3 5512 μmol/L, CKD4-5 4388 μmol/L, P<0.001) and urinary sodium (CKD1-2 111.4 mmol/L, CKD3 75.8 mmol/L, CKD4-5 73.2 mmol/L, P<0.001) decreased significantly. The resistance index of bilateral renal hilar artery (right CKD1-2 0.69,CKD3 0.77,CKD4-5 0.74, P=0.010, left CKD1-2 0.69, CKD3 0.76, CKD4-5 0.78, P=0.009) and segmental artery resistance index (right CKD1-2 0.66,CKD3 0.71,CKD4-5 0.72, P=0.034, left CKD1-2 0.66, CKD3 0.69, CKD4-5 0.73, P=0.027) also increased with the progression of CKD stage. Multivariate logistic regression analysis showed that higher blood retinol binding protein (OR 1.073, 95% CI 1.006-1.145; P=0.032) and serum β 2-microglobulin (OR 1.932, 95% CI 1.233-3.027; P=0.004) were independent risk factors for the progression of CKD4-5 in patients with chronic liver disease complicated with CKD.Conclusion Active monitoring of blood and urine biomarkers in patients with CKD in combination with chronic liver disease can help detect the progression of CKD in patients with chronic liver disease at an early stage and facilitate early intervention and prognosis improvement.

Key words: Chronic liver disease, Chronic kidney disease, Clinical features, Risk factors

康玮玮, 刘立伟, 张嫄, 钟蕊, 冯丽丽, 陈煜. 慢性肝病合并慢性肾脏病患者的临床特征分析[J]. 肝脏, 2023, 28(5): 518-522.

KANG Wei-wei, LIU Li-wei, ZHANG Yuan, ZHONG Rui, FENG Li-li, CHEN Yu. Clinical characteristics of nephropathy in patients with chronic liver disease combined with chronic kidney disease[J]. Chinese Hepatolgy, 2023, 28(5): 518-522.

参考文献

[1] Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol, 2020,18(12):2650-2666.
[2] Gonwa TA, Wadei HM. Kidney disease in the setting of liver failure: core curriculum 2013. Am J Kidney Dis, 2013,62(6):1198-212.
[3] Desai AP, Knapp SM, Orman ES, et al. Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis-a US population-based study. J Hepatol, 2020,73(5):1092-1099.
[4] Gu J, Yu G, Zhang X, et al. Cross-sectional retrospective analysis of clinical characteristics of chronic hepatitis B patients with oral antiviral treatment in eastern China. Virol J, 2021,18(1):19.
[5] Wong F, Reddy KR, O'Leary JG, et al. Impact of chronic kidney disease on outcomes in cirrhosis.Liver Transpl, 2019,25:870-880.
[6] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版).临床肝胆病杂志,2019,35(12):2648-2669.
[7] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2019年版).中华肝脏病杂志,2019,27(12):962-979.
[8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南(2018更新版).中华肝脏病杂志, 2018,26(3):188-194.
[9] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版).中华肝脏病杂志,2018,26(3):195-203.
[10] 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南.中华肝脏病杂志,2015,23(11):810-820.
[11] 中华医学会肝病学分会.肝硬化诊治指南.中华肝脏病杂志,2019,27(11):846-865.
[12] Younossi ZM, Bernstein D, Shiffman ML, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol, 2019,114(1):48-63.
[13] Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med, 2013,158(11):825-30.
[14] 刘虹,彭佑铭,李娟,等.3547例慢性肾脏疾病患者分期及相关因素分析.中南大学学报(医学版),2010,35(5):499-510.
[15] 于乐成,汪茂荣,何长伦.肝硬化急性肾损伤诊治进展. 传染病信息, 2014,27(2):69-73.
[16] De Silva ST, Perera RP, Niriella MA, et al. Frequency, pattern and short-term outcome of chronic renal dysfunction in patients with cirrhosis: a prospective study using HRS and ADQI-IAC criteria. Eur J Gastroenterol Hepatol, 2014,26(11):1296-1299.
[17] Fida S, Khurshid SMS, Mansoor H. Frequency of hepatorenal syndrome among patients with cirrhosis and outcome after treatment. Cureus, 2020,12(8):e10016.
[18] 杨秋辉.肝硬化患者心脏血流动力学及肾功能的研究.天津:天津医科大学,2015.
[19] George JA, Gounden V. Novel glomerular filtration markers. Adv Clin Chem, 2019,88:91-119.
[20] Bergwik J, Kristiansson A, Allhorn M, et al. Structure, functions, and physiological roles of the lipocalin α1-microglobulin (A1M). Front Physiol, 2021,12:645650.
[21] Xiong S, Qi T, Gong N, et al. Correlation and diagnostic value of serum RBP4 and sRAGE and the condition of patients with chronic kidney disease. Evid Based Complement Alternat Med, 2021:6166528.
[22] Ascher SB, Scherzer R, Estrella MM, et al. Urine Biomarkers of Kidney Tubule Health and Incident CKD Stage 3 in Women Living With HIV: A Repeated Measures Study. Kidney Med, 2021,3(3):395-404.e1.
[23] Jotwani V, Garimella PS, Katz R, et al. SPRINT Research Group. Tubular Biomarkers and Chronic Kidney Disease Progression in SPRINT Participants. Am J Nephrol, 2020,51(10):797-805.
[24] Rebholz CM, Inker LA, Chen Y, et al. Chronic Kidney Disease Biomarkers Consortium. Risk of ESRD and Mortality Associated With Change in Filtration Markers. Am J Kidney Dis, 2017,70(4):551-560.
[25] Phanish MK, Chapman AN, Yates S, et al. Evaluation of Urinary Biomarkers of Proximal Tubular Injury, Inflammation, and Fibrosis in Patients With Albuminuric and Nonalbuminuric Diabetic Kidney Disease. Kidney Int Rep, 2021,6(5):1355-1367.
[26] 朱永俊,俞容,曹彦卫,等.慢性肾脏病患者肾动脉阻力指数变化及其与早期肾功能损伤的相关性研究.临床肾脏病杂志, 2021,21(8):654-659.
[27] Cui G, Yang Z, Zhang W, et al. Evaluation of acoustic radiation force impulse imaging for the clinicopathological typing of renal fibrosis. Exp Ther Med, 2014,7(1):233-235.
[28] Kumar R, Priyadarshi RN, Anand U. Chronic renal dysfunction in cirrhosis: a new frontier in hepatology. World J Gastroenterol, 2021,27(11):990-1005.
[29] 郝坤艳,于乐成.肝病时肾损伤和肾功能不全评估的若干问题.临床肝胆病杂志,2016,32(8):1483-1487.